Clinical Trial

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is an open label, randomized, phase Ⅲ study to treat subjects with RAS/BRAF wild-type, unresectable metastatic colorectal cancer. The patients will be randomized into two arms consist of Anlotinib (3 weeks/cycle) + CapeOx and Bevacizumab (3 week/cycle) + CapeOx at a ratio of 1:1. This study is conducted to assess the efficacy and safety of Anlotinib and Chemotherapy as first-line treatment in subjects with RAS/BRAF wild-type Metastatic Colorectal Cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-04-21; most recent amendment 2026-01-29.
Status change: Recruiting → Active, Not Recruiting 2023-11-30
Status change: Not Yet Recruiting → Recruiting 2021-08-17
Trial Details
NCT Number NCT04854668
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Metastatic Colorectal Cancer
Enrollment 748 participants
Start Date 2021-05-27
Primary Completion 2024-12-31 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-30